#1Baxter Critical Care Scan this barcode, or program manually. care area OMO Win 09 8675309 را O program manually ABC JKL OK DEF 2 GHI VWX 8 MNO PQR అన వారి STU 7 SpectrumlQ Baxter MEDICATION DELIVERY David Ferguson GM, Medication Delivery May 21, 2018#2Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval) and results of clinical trials, business development activities, capital structure, cost savings initiatives, Baxter's long range plan (which includes financial outlook for 2018, 2020 and 2023) and other growth strategies. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward- looking statements: demand for and market acceptance of risks for new and existing products; product development risks; product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster or otherwise); breaches or failures of Baxter's information technology systems, including by cyberattack; future actions of regulatory bodies and other governmental authorities, including FDA, the Department of Justice, the New York Attorney General and foreign regulatory agencies; failures with respect to compliance programs; future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; global, trade and tax policies; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the recent acquisitions of Claris Injectables and two surgical products from Mallinckrodt plc); the ability to enforce owned or in-licensed patents or the patents of third parties preventing or restricting manufacture, sale or use of affected products or technology; the impact of global economic conditions; fluctuations in foreign exchange and interest rates; any change in law concerning the taxation of income (including current or future tax reform), including income earned outside the United States; actions taken by tax authorities in connection with ongoing tax audits; loss of key employees or inability to identify and recruit new employees; the outcome of pending or future litigation; the adequacy of Baxter's cash flows from operations to meet its ongoing cash obligations and fund its investment program; and other risks identified in Baxter's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. Baxter 12#3Medication Delivery Market Overview¹ Global Market Size Baxter ~$23B 2018 CAGR² IV Therapies ~3% 2% -3% ~$27B 2023 Infusion Systems IV Therapies Comprehensive portfolio of essential IV solutions Infusion Systems Infusion pumps and disposables for delivery of IV therapy Medication Delivery Market Is Expected To Grow ~3% Through 2023² #1 U.S. Baxter Position #2 U.S. Baxter Position ¹Market estimates and Baxter position based on internal estimates. 22018-2023 Compounded Annual Growth Rate. | 3#4Medication Delivery Market Dynamics. Supply Constraints AHTAR Baxter IV solution supply issues continue to challenge healthcare providers Preventable dverse Events 1.2M preventable adverse events per year associated with injectable medications¹ Hospital Cost Pressures Consistent pressure to reduce expenditures and streamline care Medication Errors 98,000 deaths per year related to medication errors² Opportunity To Reduce Cost Pressure, Increase Efficiency And Avoid Medication Errors To Enhance Care For Patients And Customers 1,2See slide 14 for references. I 4#5#6#7#8#9#10#11#12#13#14#15